Tuesday - May 12, 2026
GSK Enters Exclusive Collaboration With SBP Group, a Market Leader in Hepatology in China, to Accelerate Bepirovirsen at Launch
May 12, 2026
LONDON, England, May 12 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on ay 11, 2026:

* * *

GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch

* Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B, under priority regulatory review in China

* Chronic hepatitis B affects 75 million people in Chi . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products